Stereotactic body radiation therapy for sarcoma pulmonary metastases

[1]  Narasimhan P. Agaram,et al.  Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma , 2022, Nature Communications.

[2]  Narasimhan P. Agaram,et al.  Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma , 2022, Nature Communications.

[3]  S. Singer,et al.  Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Narasimhan P. Agaram,et al.  Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets , 2021, Nature Communications.

[5]  Jacob G. Scott,et al.  Safety of Metastasis-Directed SBRT and Concurrent Pazopanib in Pediatric Sarcoma , 2020 .

[6]  Kevin B. Jones,et al.  The epigenomics of sarcoma , 2020, Nature Reviews Cancer.

[7]  I. Shin,et al.  Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review , 2020, npj Precision Oncology.

[8]  C. Simone,et al.  Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity , 2020, Journal of surgical oncology.

[9]  B. Yaremko,et al.  Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial , 2019, BMC Cancer.

[10]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Riedel,et al.  Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma , 2018, Cancer.

[12]  J. Galvin,et al.  Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial , 2018, JAMA oncology.

[13]  J. Galvin,et al.  Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[14]  E. Yorke,et al.  Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) , 2018, Acta oncologica.

[15]  D. Kirsch,et al.  Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[16]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[17]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[18]  B. Corn,et al.  Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients , 2017, American journal of clinical oncology.

[19]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[20]  L. Uhlmann,et al.  Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.

[21]  K. Rosenzweig,et al.  Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. , 2016, Clinical lung cancer.

[22]  N. Araki,et al.  The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study , 2016, Cancer.

[23]  E. Yorke,et al.  Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. , 2016, Practical radiation oncology.

[24]  A. Chaudhuri,et al.  Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. , 2015, Lung cancer.

[25]  H. Gelderblom,et al.  Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series , 2014, Clinical Sarcoma Research.

[26]  E. Yorke,et al.  Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[28]  Wen Gao,et al.  Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. , 2012, The Annals of thoracic surgery.

[29]  H. Ott,et al.  Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. , 2011, The Annals of thoracic surgery.

[30]  J. Wunder,et al.  Soft tissue sarcoma presenting with metastatic disease , 2011, Cancer.

[31]  S. Siva,et al.  Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  J. Roth,et al.  Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.

[33]  R. Grimer,et al.  Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. , 2008, European journal of cancer.

[34]  E. Yorke,et al.  High-Dose Radiotherapy for the Treatment of Inoperable Non–Small Cell Lung Cancer , 2007, Cancer journal.

[35]  Samuel Ryu,et al.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. , 2004, International journal of radiation oncology, biology, physics.

[36]  M. Ferguson,et al.  Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. , 2003, The Annals of thoracic surgery.

[37]  C C Ling,et al.  The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. , 2000, International journal of radiation oncology, biology, physics.

[38]  M. Burt,et al.  Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. , 1999, Annals of surgery.

[39]  D H Leung,et al.  Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma , 1999, Cancer.

[40]  S. Rosenberg,et al.  Patterns of recurrence in patients with high-grade soft-tissue sarcomas. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.